ARVO 2023: Research on epigenetic reprogramming to reverse aging and restore function to RGCs
April 29th 2023Our onsite team spoke with Bruce Ksander, PhD, at the 2023 ARVO annual meeting, where he discussed his presentation about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells.
Read More
Nanoscope Therapeutics Inc. presented key data at the ARVO 2023 annual meeting regarding their from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010, which has received both orphan drug and fast track designations from the FDA.
Read More
D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Read More
ARVO 2023: Carl Danzig, MD, FASRS shares new data on vision loss from the GATHER clinical program
April 25th 2023Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.
Read More
ARVO 2023: T. Y. Alvin Liu, MD discusses predictive AI and its application in ophthalmology
April 25th 2023At the 2023 ARVO annual meeting in New Orleans, our on-site team caught up with T. Y. Alvin Liu, MD, to discuss predictive AI and its application in ophthalmology and screening of the eyes.
Read More
ARVO 2023: Using donor tissue to identify the mechanism cell death of the RPE
April 25th 2023Deborah Ferrington, PhD, spoke with on our on-site team at the 2023 ARVO annual meeting in New Orleans about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium (RPE).
Read More
ARVO 2023: Luxa Biotechnology shares progress of Phase 1/2a clinical trial for AMD treatment
April 25th 2023At ARVO in New Orleans, Luxa Biotechnology shared an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD).
Read More